Share

April 30, 2013; 80 (18) Article

Adherence to a Mediterranean diet and risk of incident cognitive impairment

Georgios Tsivgoulis, Suzanne Judd, Abraham J. Letter, Andrei V. Alexandrov, George Howard, Fadi Nahab, Frederick W. Unverzagt, Claudia Moy, Virginia J. Howard, Brett Kissela, Virginia G. Wadley
First published April 29, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182904f69
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
853

Share

Article Information

vol. 80 no. 18 1684-1692
DOI: 
https://doi.org/10.1212/WNL.0b013e3182904f69
PubMed: 
23628929
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received September 20, 2012
  • Accepted in final form January 22, 2013
  • First Published April 29, 2013.
Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Georgios Tsivgoulis, MD,
    2. Suzanne Judd, PhD,
    3. Abraham J. Letter, MS,
    4. Andrei V. Alexandrov, MD,
    5. George Howard, DrPH,
    6. Fadi Nahab, MD,
    7. Frederick W. Unverzagt, PhD,
    8. Claudia Moy, PhD,
    9. Virginia J. Howard, PhD,
    10. Brett Kissela, MD and
    11. Virginia G. Wadley, PhD
  1. Georgios Tsivgoulis, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Suzanne Judd, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Abraham J. Letter, MS,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. WL Gore and Associates, Clinical Biostatistician since Jan 2012 working on clinical studies of aortic endoprostheses

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Andrei V. Alexandrov, MD,
    5. Scientific Advisory Boards:

    1. Commercial entity: Cerevast Therapeutics, Inc

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Brain and Behavior, Editor-in-Chief, 2011 - present Stroke, Editorial Board member, 1998 - present International Journal of Stroke, Associate Editor 2006- 2011 Cerebrovascular Diseases, Editorial Board member, 2011- present

    Patents:

    1. “Therapeutic Methods and Apparatus for Use of Sonication to Enhance Perfusion of Tissue” Inventors: Alexandrov AV, Aronowski J, Wojner AW US patent 6,733,450 (May 11, 2004) Assignee: Texas Systems, Board of Reagents

    Publishing Royalties:

    1. Alexandrov AV. Cerebrovascular Ultrasound in Stroke Prevention and Treatment. New York: Futura / Blackwell Publishing. 2003. ISBN 1- 4051-0381-7 Alexandrov AV. Cerebrovascular Ultrasound in Stroke Prevention and Treatment. Oxford: Blackwell Publishing (in Chinese) 2007. ISBN 7- 117-07389-6 Alexandrov AV. Cerebrovascular Ultrasound in Stroke Prevention and Treatment. (2nd Edition) Oxford: Wiley-Blackwell Publishers. 2011. 9781405195768.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Commercial entity: Cerevast Therapeutics, Inc.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Comprehensive Stroke Center, UAB Hospital 60% effort on clinical stroke service; monitoring endovascular procedures and evaluating success of recanalization with imaging. 2007-till present.

    Research Support, Commercial Entities:

    1. Commercial entity: Cerevast Therapeutics, Inc.

    Research Support, Government Entities:

    1. NINDS, Project 4 CLOTBUST-Hands Free of the SPOTRIAS: University of Texas Specialized Program in Translational Research in Acute Stroke

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Commercial entity: Cerevast Therapeutics, Inc.

    License fee payments, Technology or Inventions:

    1. “Therapeutic Methods and Apparatus for Use of Sonication to Enhance Perfusion of Tissue” Inventors: Alexandrov AV, Aronowski J, Wojner AW US patent 6,733,450 (May 11, 2004) Assignee: Texas Systems, Board of Reagents Source of payment: Cerevast Therapeutics, Inc.

    Royalty Payments, Technology or Inventions:

    1. “Therapeutic Methods and Apparatus for Use of Sonication to Enhance Perfusion of Tissue” Inventors: Alexandrov AV, Aronowski J, Wojner AW US patent 6,733,450 (May 11, 2004) Assignee: Texas Systems, Board of Reagents Source of payment: Cerevast Therapeutics, Inc.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. George Howard, DrPH,
    6. Scientific Advisory Boards:

    1. ARRIVE Study Executive Committee Board for Bayer Healthcare; served as a consultant in for an FDA application for Abbott Vascular; Advisory board for Boehringer Ingelheim, Brainsgate, Cerevast, CoAxia, LifeVest, MediciNova, Mitsubishi, and PhotoThera

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Stroke Section Editor Stroke and Cerebrovascular Disease Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Amgen - Treatment of Early Agressive Rheumatoid Arthritis - TEAR

    Research Support, Government Entities:

    1. NINDS, PI, REasons for Geographic And Racial Differences in Stroke - REGARDS (NS41588) NINDS, co-PI of Coordinating Center, Carotid Revascularization Endarterectomy Stenting Trial - CREST (NS38384) NIAMS, co-PI, Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis - (AR02247) NICHD, co-PI, Vaginal Ultrasound Cerclage Trial HD39939 NINDS, co-I, Secondary Prevention of Small Subcortical Stroke - SPS3 (NS038529) NHLBI, co-I, SCCOR in Cardiac Dysfunction, (HL77100) NINDS, co-I, Psychosocial impact of stroke on family caregivers (NS34789)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1) Pfizer legal issues, consultant, 2012

  6. Fadi Nahab, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. National Stroke Association speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Frederick W. Unverzagt, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neuropsychology, Editorial Board, 2007-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. UCB Pharma

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Posit Science Inc.

    Research Support, Government Entities:

    1. R01 AG026096, PI, 2006-2011 U01 NR004508, PI, 2008–2011 R01 AG09956, CoI, 1991-2011 P30 AG10133, CoI, 1991-2011 U01 NS041588, CoI, 2007-2012 ITRAC, PI, 2008-2009 RSGPB04-089-01-PBP, ACS, CoI, 2004-2009

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Eli Lilly

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Claudia Moy, PhD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. currently a Federal government employee

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Virginia J. Howard, PhD,
    10. Scientific Advisory Boards:

    1. Self - (1) Serve on DSMB for NIH-NIDA Immediate family member scientific advisory boards for: (1) NHLBI cohort study, (2) the ARRIVE Study (Bayer Healthcare) Spouse served on DSMBs for: (1) PhotoThera, (2) Medicinova, (3) Univ of London

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Personal - NIH review committees Immediate family member consulting: NIH review committees

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Self: 1) NIH-NINDS, NS41588, co-PI, 2001- present, (2) NIH-NINDS, NS38384, co-investigator, 1999-present, (3) NIH-NINDS NS061846, co- investigator, 2008-present, (4) NIH-NIA AG039588, PI, 2011-present (5) CDC, FY10OHDLZCO, 2009-present, co- investigator. Spouse: 1) NIH-NINDS, NS41588, co-PI, 2001- present, (2) NIH-NINDS, NS38384, co-investigator, 1999-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Brett Kissela, MD and
    11. Scientific Advisory Boards:

    1. (1) for Allergan with compensation (scientific advisor)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Allergan, travel costs and honoraria for speaking

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Reata Pharmaceuticals--I will receive compensation to serve on the Event Adjudication Committee for the BEACON study, which they are sponsoring

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH funding for multiple grants

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. I have served as an expert witness in medicolegal cases related to stroke within the prior 2 years. In this capacity, I have performed chart reviews and been deposed on one occassion.

  11. Virginia G. Wadley, PhD
    12. Scientific Advisory Boards:

    1. (1) Amgen, Inc. Scientific Advisory Board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Amgen, Inc., travel expenses and honorarium

    Editorial Boards:

    1. Current Gerontology and Geriatrics Research, editoral board, 2010-present, no compensation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Genzyme Therapeutics, investigator-initiated grant, PI

    Research Support, Government Entities:

    1. (1)NIH, NO1 HC48047, Co-I, 1989-2013 (2)NIH, U01 NS51488, Co-I, 2007-2012 (3)NIH, R01 NS061846,Co-I, 2008-2013 (4)NIH, P30 AG022838,Co-I,2009-2014 (5)NIH, HHSN268200900047C, Co-I, 2009–2018 (6)NIH, R01 AG021958, Co-I, 2009–2014 (7)NIH, R01 AG039588, Co-I, 2011-2016 (8)Jefferson County [AL] Office of Senior Citizens Services, PI, 2006–2011 (9)NIH, R01 NS45789, Co-I. 2005-2011 (10)NIH, U01 AG14289, Co-I, 2008-2011 (11)NIH, R01 AG005739, Co-I, 2006–2011

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Second Department of Neurology, School of Medicine, Attikon Hospital, University of Athens, Greece; Comprehensive Stroke Center (G.T., A.V.A.), the Departments of Biostatistics (S.J., A.J.L., G.H.) and Epidemiology (V.J.H.), School of Public Health, and the Department of Medicine (V.G.W.), University of Alabama at Birmingham, Birmingham; International Clinical Research Center (G.T.), St. Anne's University Hospital Brno, Brno, Czech Republic; the Department of Neurology (F.N.), Emory University, Atlanta, GA; the Department of Psychiatry (F.W.U.), Indiana University School of Medicine, Indianapolis; National Institute of Neurological Disorders and Stroke (C.M.), National Institutes of Health, Bethesda, MD; and the Department of Neurology (B.K.), University of Cincinnati, Cincinnati, OH. Coinvestigators are listed on the Neurology® Web site at www.neurology.org.
  1. Correspondence to Dr. Tsivgoulis: tsivgoulisgiorg{at}yahoo.gr
View Full Text

Article usage

Article usage: April 2013 to May 2021

AbstractFullPdfSource
Apr 201328442664Highwire
May 2013769988202Highwire
Jun 201310031523Highwire
Jul 20135341513Highwire
Aug 2013374128Highwire
Sep 2013419813Highwire
Oct 201361854Highwire
Nov 201343236Highwire
Dec 201330986Highwire
Jan 201424745Highwire
Feb 201430629Highwire
Mar 201426033Highwire
Apr 201419665Highwire
May 201419812Highwire
Jun 201416213Highwire
Jul 201415220Highwire
Aug 201415943Highwire
Sep 201417431Highwire
Oct 201448324Highwire
Nov 201421311Highwire
Dec 201417524Highwire
Jan 201516702Highwire
Jan 2015097pmc
Feb 201526225Highwire
Feb 2015096pmc
Mar 201559453Highwire
Mar 201503213pmc
Apr 201523512Highwire
Apr 20150196pmc
May 201532112Highwire
May 20150127pmc
Jun 201512601Highwire
Jun 20150218pmc
Jul 201513521Highwire
Jul 20150639pmc
Aug 201561411Highwire
Aug 20150649pmc
Sep 201534611Highwire
Sep 20150548pmc
Oct 201528014Highwire
Oct 2015073pmc
Nov 201520914Highwire
Nov 201503016pmc
Dec 201518411Highwire
Dec 20150114pmc
Jan 201615300Highwire
Jan 20160106pmc
Feb 201610523Highwire
Feb 20160168pmc
Mar 201610901Highwire
Mar 201601414pmc
Apr 20169200Highwire
Apr 20160112pmc
May 201617111Highwire
May 20160205pmc
Jun 201616900Highwire
Jun 20160154pmc
Jul 201611300Highwire
Jul 2016043pmc
Aug 201611500Highwire
Aug 201601512pmc
Sep 20168701Highwire
Sep 20160168pmc
Oct 201610801Highwire
Oct 201602811pmc
Nov 201611800Highwire
Nov 20160149pmc
Dec 20169621Highwire
Dec 20160135pmc
Jan 201710711Highwire
Jan 20170126pmc
Feb 201711611Highwire
Feb 201703614pmc
Mar 201711012Highwire
Mar 201704015pmc
Apr 20177402Highwire
Apr 2017111818pmc
May 20175111Highwire
May 201781820pmc
Jun 20175001Highwire
Jun 201751112pmc
Jul 20175100Highwire
Jul 2017444pmc
Aug 20175411Highwire
Aug 201741523pmc
Sep 20175300Highwire
Sep 201771110pmc
Oct 20174000Highwire
Oct 2017122131pmc
Nov 20173812Highwire
Nov 2017102127pmc
Dec 20174700Highwire
Jan 20188000Highwire
Feb 20187451Highwire
Mar 20188831Highwire
Apr 20186800Highwire
Apr 2018101514pmc
May 201812302Highwire
Jun 201810711Highwire
Jun 2018489pmc
Jul 201814721Highwire
Aug 201814311Highwire
Aug 201851212pmc
Sep 201816500Highwire
Oct 201818823Highwire
Nov 201821821Highwire
Dec 201818021Highwire
Jan 201916810Highwire
Feb 201917702Highwire
Mar 201917710Highwire
Apr 201917231Highwire
May 201914811Highwire
Jun 201912400Highwire
Jul 201914401Highwire
Aug 201914210Highwire
Sep 201916311Highwire
Oct 201916201Highwire
Nov 201919000Highwire
Dec 201916402Highwire
Jan 202011410Highwire
Feb 202010710Highwire
Mar 202011700Highwire
Apr 202011300Highwire
May 202011231Highwire
Jun 202011101Highwire
Jul 202010220Highwire
Aug 202011211Highwire
Sep 202013320Highwire
Oct 202014630Highwire
Nov 202012810Highwire
Dec 202012200Highwire
Jan 202116311Highwire
Feb 202112122Highwire
Mar 202114900Highwire
Apr 202115501Highwire
May 202116612Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me